Fibrosis in Chronic Kidney Disease. Protagonista and Therapy
Laura S. Villanueva1*, Begona Santos S. Rey2
1Department of Nephrology, Hospital universitario de la Princesa, Madrid, Spain
2Begoña Santos Sanchez Rey, Department of Nephrology, Hospital universitario de la Princesa, Madrid. Spain

Received: August 9, 2016; Accepted: August 12, 2016; Published: August 21, 2016
*Corresponding author: Laura Salanova Villanueva, Department of Nephrology, Hospital universitario de la Princesa, Madrid, Spain, Tel: +605645894; Email: aelita.sv@gmail.com

Abstract
Chronic kidney disease is a serious public health problem, for its high incidence and prevalence and its significant morbidity and mortality. Fibrosis is the end of all impaired renal failure. The fibrotic process is characterized by infiltration of inflammatory cells (T cells, macrophages etc), cytokine releases, activation of fibroblasts and activation of numerous chemical signals. This process involves effector cells generation which produce extracellular matrix leading to organ damage. No therapy has demonstrated efficacy 100% against fibrotic damage. Vitamin D and its analogues can exert their immunomodulation through the regulation of the activity of many types of immune cells and present an ant fibrotic profile.

Keywords: Fibrosis; Chronic kidney disease; Epithelial mesenchymal transition; Vitamin D

Introduction
Nephron is kidney functional unit. It composed of glomerulus, Bowman's capsule, a complex tubular network, the interstitium, juxtaglomerular apparatus and a complex interweaving of vessels. Glomerulus is responsible for plasma ultrafiltrate formation [1,2].

Tubule-interstitial network represents 80% of renal volume. This network consists in [1,2]:

- Interstitial cells type I: fibroblasts like that are responsible for the synthesis and degradation of Extracellular Matrix (ECM).
- Interstitial cells type II: monocyte-derived macrophages and dendritic cells.
- Matrix: collagen, proteoglycans, glycoproteins, interstitial fluid.
- Tubular cells: responsible for substances transport.
- Specialized cells: juxtaglomerular cells renin-producing, tubular cells which produce active vitamin D, erythropoietin, Klotho.

Kidney aggression leads to an inflammatory and reparative response which could lead in a fibrotic response that carries permanent kidney damage. Here we review fibrosis process in the kidney and signals and molecules that could influence in this process as well as potential therapeutic drugs.

Fibrosis process in Chronic Kidney Disease (CKD)
Progressive fibrosis is the final common pathway for all kidney diseases leading to chronic renal failure. Its presence correlates with impaired excretory function and the degree of fibrosis or fibroblasts number are markers of progression [3]. Chronic infections, toxic and metabolic injuries, and idiopathic inflammatory diseases can promote the development of fibrosis [3]. Renal disease offers a favorable microenvironment for fibrotic process: increased cytokines and inflammatory substances, profibrotic growth factors, ECM deposition: collagen type I, III, IV, proteoglycans and fibronectin [3,4], reactive oxygen species (ROS) [3] etc. Cytokines act as pleiotropic polypeptides synthesized by different types of cells, causing paracrine, yuxtacrin and autocrine effects which can regulate immune and inflammation response [5].

These factors accelerate programmed cell death (apoptosis), an inflammatory process that involves fibrosis and an alteration of cell profile in glomerular and tubular interstitial cells. Cells undergo a phenotypic conversion called Epithelial-Mesenchymal Transition (EMT), although there are studies that question this process in the kidney and consider that the process of fibrosis is not because EMT [3-7]. Fibroblasts and myofibroblast also increase which cause matrix-production.

Fibroblasts are key mediators of fibrosis in the kidney and other organs, but their origin is still not completely clear [3]. Activated fibroblasts likely arise from resident quiescent fibroblasts via epithelial-to-mesenchymal transition and from the bone marrow. Fibroblast is a connective tissue cell derived from mesenchymal stem cells or leukocyte, it could secrete different proteins such as procollagen, and proteoglycans to form part of ECM [8,9]. Myofibroblast is a special fibroblast that has developed some smooth muscle cells characteristics that
Damage to tubular epithelial cells produce various chemokines filtratin barrier function, and proteinuria can be induced [11]. EMT factors Snail. As a result, these alterations impair podocytes’ interstitial matrix components and up regulate the transcription intermediate filament protein desmin, secret MMP-9, produce the proteins P-cadherin, ZO-1, and nephrin and begin to express the growth factor β (TGF-β), reduce the slit diaphragm-associated pathologic conditions. Upon incubation with transforming are specialized visceral epithelial cells also undergo EMT under CD31, collagen I, fibronectin [7-10]. Glomerular cells podocytes characteristic features of mesenchyme such as α−SMA, vimentin, E-cadherin, Zonula ocludens 1 (ZO-1) etc and acquire new characteristic features of mesenchymal cells [6-10]; it is a potentially reversible process.

Epithelial mesenchymal transition

EMT is a process where differentiated epithelial cells undergo a phenotypic conversion that involves fibroblast and myofibroblast matrix-producing, it is recognized as an integral part of tissue fibrogenesis after injury [6-10]. EMT concept was formulated in embryonic development and in tumor metastases. Tubular and glomerular renal cells lose their epithelial phenotype and acquire new characteristic features of mesenchymal cells [6-10]; it is a potentially reversible process.

Epithelial cells lose their phenotype and markers such as E-cadherin, Zona ocludens 1 (ZO-1) etc and acquire new characteristic features of mesenchyme such as α-SMA, vimentin, CD31, collagen I, fibronectin [7-10]. Glomerular cells podocytes are specialized visceral epithelial cells also undergo EMT under pathologic conditions. Upon incubation with transforming growth factor β (TGF-β), reduce the slit diaphragm-associated proteins P-cadherin, ZO-1, and nephrin and begin to express the intermediate filament protein desmin, secret MMP-9, produce the interstitial matrix components and up regulate the transcription factor Snail. As a result, these alterations impair podocytes' filtration barrier function, and proteinuria can be induced [11]. Damage to tubular epithelial cells produce various chemokines and cytokines secretion in response to stresses (glucose, hypoxia, ROS, autoimmune reaction etc), this process attract inflammatory cells (monocytes, macrophages and lymphocytes) to the tubulointerstitial area creating a microenvironment in which cells modify their phenotype for the sake to avoid apoptosis [11].

Different growth factors and cytokines such as TGF β, connective tissue growth factor (CTGF), nuclear factor κ Beta (NF-B) assist EMT process. E-Cadherin reduction plays a central role in mesothelial cells (MC) EMT [1,2]. An important E-Cadherin repressor is transcription factor Snail, infact Snail is a potent EMT inducer and vitamin D receptor (VDR) inhibitor [13].

A similar process occurs in Peritoneal Membrane (PM) on Peritoneal Dialysis (PD) patients. Peritoneal MCs suffer a disruption of intercellular junctions and loss of the apical-basolateral polarity of epithelial cells, finally cells are transformed into fibroblast like cells with increased migratory, invasive, and fibrogenic features [14]. This process is due to continuous exposure to bioincompatible dialysis fluids, peritonitis, hemoperitoneum which causes progressive fibrosis and angiogenesis and, ultimately, ultra filtration failure [14,15]. EMT not only affects to MC but also to adiposities, leukocytes, fibroblasts and peritoneal vascular cells.

Table 1: Cells marker; HSP47: Shock Hot Protein 4; ICAM: Intracellular Adhesion Molecule 1; α SMA: α Smooth Muscle Actin; DDR2: Diisocidin Domain Receptor 2; NG2: Neuroglial Antigen 2; PDGFR: Platelet Derived Growth Factor; FSP1: fibroblast specific protein 11.

<table>
<thead>
<tr>
<th>Cell Types</th>
<th>Cells markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibroblasts</td>
<td>FSP1, HSP47, C44, ICAM, DDR2</td>
</tr>
<tr>
<td>Myofibroblasts</td>
<td>α SMA</td>
</tr>
<tr>
<td>Peritones</td>
<td>α SMA, NG2, PDGFR2, Desmin</td>
</tr>
<tr>
<td>Vascular smooth muscle cells</td>
<td>α SMA, calponin, caldesmon</td>
</tr>
<tr>
<td>Mesenchimal stem cells</td>
<td>FSP1</td>
</tr>
</tbody>
</table>

TGF-β Effects over Kidney

<table>
<thead>
<tr>
<th>Glomerulus</th>
<th>Podocyte apoptosis:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Podocyte depeletion</td>
</tr>
<tr>
<td></td>
<td>- Glomerular tuft adhesion</td>
</tr>
<tr>
<td>Endothelial cells apoptosis:</td>
<td>Decrease endothelial cell survival</td>
</tr>
<tr>
<td></td>
<td>- Glomerular capillary loss</td>
</tr>
<tr>
<td>Mesangial cell activation:</td>
<td>- EMC accumulation</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubulointerstitial area</td>
<td>Epithelial cells apoptosis:</td>
</tr>
<tr>
<td></td>
<td>- Tubular degeneration</td>
</tr>
<tr>
<td></td>
<td>- Tubular atrophy</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>TGF β</td>
<td>EMT:</td>
</tr>
<tr>
<td></td>
<td>- Tubular degeneration</td>
</tr>
<tr>
<td></td>
<td>- Fibroblast activation</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fibroblast activation:</td>
</tr>
<tr>
<td></td>
<td>- ECM accumulation</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubular degeneration:</td>
<td>Endothelial survival decrease</td>
</tr>
<tr>
<td></td>
<td>- Tubular atrophy</td>
</tr>
<tr>
<td></td>
<td>- Peritubular capillary loss</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1: Fibrosis Consequences in Glomerulus and Tubulointerstitial Area; ROS: Reactive Oxygen Species; TGF-β: Transforming Growth Factor β; NFκB: Nuclear Factor κ Beta

Inflammatory and fibrosis relevant signals

T helper 17 cells (THC17) / interleukin (IL) 17: represent T helper cells subsets that secrete IL specially IL17 and other cytokines. They have been associated with autoimmune and chronic inflammatory diseases [16]. There is an equilibrium between THC17 cells and regulatory T cells; this balance relies on RORyt (Transcription factor retinoic acid receptor-related orphan receptor t), Stat 3 and 5 (transduction and activator signal 3 and 5) and FoxP3 (forkhead box P3). In this way immune response is regulated by pro and anti inflammatory cytokines [17-19]. The most important cytokines that regulate balance of regulatory T cells and THC17 are TGF-β and IL6 [20]. THC17 cause cytokines secretion (IL6, IL17 A-17F, IL 22) which could trigger an inflammatory process. Among these cytokines 17A represents a greater inflammatory effect and promotes collagen synthesis in fibrosis models [21]. On the other hand, regulatory T cells, dropped in CKD, prevent fibrocytes and collagen accumulation in different experimental models and their blockade could increase fibrosis risk and organ damage [21].

TGF-β: TGF-β superfamily consists of secreted peptides, of which the three TGF-β isoforms, (1, 2, 3), activins, and bone morphogenetic proteins (BMP) are best known. The TGF-β isoforms are widely expressed and act on every cell type in mammals by engaging a ubiquitous intracellular signaling cascade of Smad family proteins [22]. In cell nucleus receptor-activated Smad (especially Smad 2, 3) protein complexes participate in transcriptional activation of target genes related to fibrosis, inflammation and EMT [22]. TGF-β is considered one of the most important regulator of cell proliferation, differentiation, apoptosis, immune response, and ECM generation [11,22]. It is essential in EMT process, both tubular and glomerular [11]. Besides TGF-β and S mad 7 together could induce apoptosis in vitro [23]. Regardless of S mad signal, TGF β can regulate fibrosis and EMT through other signals such as RhoA protein (Ras homolog gene family member A), MAPK [24 ] (Mitogen activated protein kinase) etc. Tubular atrophy and interstitial fibrosis could be induced by a high protein content in the ultrafiltrate, and this process can generate an inflammatory reaction [26]. EMT, induced by TGF-β, could transform tubular epithelial cells into activated Myofibroblasts which involve an increase in ECM [26]. TGF-β upregulation implies a decrease in BMP and S mad 1, 5, 8 [27]. Besides TGF-β increase involves vascular damage: mesenchymal stem cells have the ability to differentiate into osteoblast cells in response to an inflammatory process, in which TGF-β is activated and up regulated. So TGF-β stimulates the mobilization of mesenchymal stem cells from bone marrow to blood circulation to the injured sites for vascular repair and remodelling [28,29].

TGF β can be stimulated by[22]: leptin, different cytokines, IL1 (increases their actions not their expression); and is inhibited by vitamin D and its analogs, celecoxib, BMP 7 and hepatocyte growth factor among others[27].

TGB-β effects over the kidneys summarized in (Table 2).

Smad family proteins: Smads are intracellular proteins that transduce extracellular signals from TGF-β, BMP and other to the nucleus where they activate downstream gene transcription [30]. Smad 2 and 3 transduce TGF-β signal; Smad 1, 5 and 8 mediate BMP 7 signal. Smad 2, 3 and 4 over expression in murine cells produce fibrosis [30]. Smad 7 inhibits NF-kB nuclear translocation process and function, NF-kB activate transcription genes with anti-apoptotic functions [31]. At nuclear level, Smad repressors are SnoN (Ski novel gene-related, non Alu-containing) and Ski (Sloan-Ketetering proto-oncogene Institute) [32]; their levels drop down during advance fibrosis damage [33].

BMPs: these proteins are part of the TGF superfamily [33]; at least, there are 30 BMPs proteins named for their osteoinductive properties that have important roles in organogenesis in a variety of tissues [33]. BMPs act by binding to a heterodimeric complex of transmembrane receptors (BMP receptor I and II), and signalling results from gene transcription stimulated through phosphorylation and nuclear translocation of regulatory Smad transcription factors [33]. The expressions of BMPs have been described in atherosclerotic plaques, vascular smooth muscle cells (VSMC) etc [34-36]; BMP 2, BMP 4, and BMP 6 have been localized to areas of vascular calcification. BMP 2 has been the most studied member of the BMP family in vascular calcification process. BMP 2 is expressed in atherosclerotic plaques [34-36] and has been shown to inhibit VSMC proliferation, relate to oxidative stress, inflammation and hyperglycemia [37].

On the other hand, BMP 7 plays a key role in mesenchymal cells transformation into bone and cartilage. Kidney is the most important site for BMP 7 synthesis and expression: glomerular podocyte and distal nephron [38]. Therefore, it is expected that in renal injury animal models BMP 7 is down regulated [39,40]. In contrast to BMP 2, BMP 7 has been shown to promote the VSMC phenotype [41,42]. BMP 7 is also important in renal homeostasis by inhibiting the EMT. It has been shown that BMP 7 expression is down regulated in kidney failure and inflammatory or ischemic reaction [43]. The addition of exogenous BMP 7 blocks the TGF-β signal and fibrosis process [27].

TNF-α (tumor necrosis factor α) [44]: it is produced mainly by monocytes, macrophages, T cells, mesangial, glomerular and tubular renal cells. Members of the TNF superfamily of cytokines regulate several cell responses, including proliferation, differentiation, and apoptosis. It also induces the synthesis and secretion of other cytokines. TWEAK (TNF like weak inducer of apoptosis), a member of the TNF family, may promote cell death, but it also modulates cell proliferation, inflammation, and angiogenesis in renal tubular cells in the presence of proinflammatory cytokines. JAK/STAT (Janus kinase / Signal transducers and activation of transcription) [45]:

Protein pairs that rapidly and efficiently transduce signalling activated by the binding of cytokines such as IL6 and G-protein. Exposure to elevated glucose concentrations results in activation of JAK2/STAT signalling in a variety of cell types as well as in the renal cortex of rodents with early diabetic nephropathy. This intracellular mechanism regulates gene expression of pro-inflammatory mediators and cell differentiation. Atherosclerosis and arterial hypertension could be influenced by JAK/STAT...
Fibrosis in Chronic Kidney Disease. Protagonista and Therapy

CTGF [46]: a member of the C-terminal cystein-rich proteins family of early response genes. CTGF increases other cytokines and chemokines expression such as MCP 1 (Monocyte chemoattractant protein-1), RANTES (regulated on activation normally T cell expressed and secreted) IL6, interferon α; and it also reduces anti-inflammatory signals such as IL10. Finally CTGF activates NF-κB pathway and in the diabetic kidney, elevated CTGF expression co-localizes with sites of EMT in the kidney.

NF-κB [47,48]: a family of pleiotropic transcription factors that integrate a network of extracellular signalling pathways, resulting in the transcriptional regulation of hundreds of genes related to inflammation, immunity, apoptosis, cell proliferation and differentiation. NF-κB belongs to Rel family proteins. Activation of NF-κB plays a role in various chronic kidney diseases associated with inflammation and fibrosis, and inhibition of NF-κB signalling effectively attenuates renal injury in experimental animals’ models. NF-κB is normally held in cytoplasm of unstimulated cells in an inactive form born to an inhibitory protein IKB. Many inflammatory genes, cytokines, glucose and viruses have joining areas to NF-κB.

VEGF (Vascular endothelial growth factor) [49,50]: VEGF family are the most critical regulator of the development of the vascular system and commonly is overexpressed in a variety of human solid tumors. It also regulates nitric oxide synthase. It has been implicated in endothelium and podocyte abnormalities in diabetic nephropathy. In CKD, VEGF levels are moody and have different implications: a deficiency decreases angiogenesis and increases apoptosis [22] but an increase could unleash macrophages recruitment. So, both low and high VEGF levels have deleterious effects over glomerular endothelium.

Leptin / adiponectin [51,52]: Adiponectin is a protein encoded by the gene protein apM1, it increases insulin sensitivity and has anti-inflammatory and anti-atherogenic actions. Leptin is considered proatherogenic and fibrogenic, stimulates renal endothelial cells and causes increased production of TGF-β and collagen type IV. Leptin also presents a vasodilator nitric oxide-dependent effect but that counteracts with rest of its actions. Both proteins increase in CKD.

Calciprotein Particles (CPP): colloidal complexes calcium apatite particles in serum. Presence of CPPs carries a proinflammatory process in endothelium [53]. In CKD, CPPs levels show a correlation between proinflammatory cytokines and all mortality causes [48].

Others signals [25]: MCP1 (recruit monocytes and macrophages in kidney inflammation process), AGEs (advanced glycation end products), B catenin (causes an important nephrin inhibition: proteinuria [11] oncostatin M, lipid renal accumulation which could inducing TGF-β expression, IL6 and 18, renin angiotensin aldosterone system (angiotensin II increases proinflammatory and profibrotic cytokines expression [54]).

Anti fibrotic Treatment. Role of Vitamin D

There is no 100% efficient treatment against fibrosis. Then we point out some molecules that have demonstrated a beneficial effect to this level:

Vitamin D and analogues: Vitamin D and analogues have an important effect over fibrosis process. We sum up some vitamin D and analogues effects against fibrosis [55-60]:

- Inhibition renin gene.
- Inhibition RANTES (regulated on activation normally T cell expressed and secreted) expression via antagonizing NF-κB activity.
- Suppres TGF-β expression as well as block directly TGF β induced EMT and ECM proteins
- Suppress TNF-α
- Increase endothelin B receptor and nitric oxide.
- Decrease proteinuria.
- Vitamin D analogues do not stimulate CBFA signal I (core binding factor alpha) in endothelium.
- Rise BMP 7 levels.

It has been shown that expression of vitamin D receptor is decreased in different fibrosis models [61,62]. In chronic kidney disease experimental models, vitamin D and analogues have shown to reduce mesangial expansion and fibronectin storage in tubulointerstitial area, prevent the expression of profibrotic growth factors (TGF-β, PAI-1 (plasminogen inhibitor 1) and CTGF) and infiltration of CD68 + and expression of proinflammatory cytokines and NF-κB [63,64]. Tan, et al. [65] investigated the effects of PRCT (subcutaneous injections 0.1-0.3 mcg / kg) on obstructive nephropathy in mouse model. Compared with vehicle controls, PRCT significantly attenuated renal interstitial fibrosis, and repressed mRNA expression of fibronectin and type I and type III collagens. It also suppressed renal TGF-β and its type I receptor expression, restored vitamin D receptor abundance, and inhibited cell proliferation and apoptosis after obstructive injury At the same time, human proximal tubular epithelial cells were incubated with various concentrations of PRCT in the absence or presence of TGF-β (2ng/ mL); PRCT inhibited the TGF-β mediated Snail induction in vitro [66]. Some investigators developed a mice mice obstructive nephropathy: They subdivided animals into five groups: sham control, obstructive nephropathy vehicle control, obstructive nephropathy mice receiving 0.3 mg/ kg paricalcitol, obstructive nephropathy mice receiving 3 mg/ kg trandolapril, obstructive nephropathy mice receiving 0.3 mg/ kg paricalcitol and 3 mg/ kg trandolapril. After 7 days PRCT inhibited the expression and accumulation of fibronectin and type I and type III collagen, suppressed α SMA, vimentin, and Snail1, RANTES and TNF-α expression, and reduced collagen [66]. Combination therapy led to a more profound inhibition of all fibrosis parameters [67]. Similar results are found in the following studies: J Yang, et al. [67] and Bottinger, et al. [68].

It remains to be determined whether TGF-β inhibition is cause or consequence of fibrosis reduction due to vitamin D and its analogues [61,69]. Vitamin D, and its analogues, directly block TGF-β effects and repress the Snail. Other studies suggest that vitamin D and its analogues are due to renin and NF-κB which lead to an anti-inflammatory and ant fibrotic effects [61,70]. Vitamin D supplementation may be a rational strategy to prevent fibrosis and EMT.

**Other treatments**

**BMP 7:** It has been shown that BMP 7 down regulates fibrotic process in different kidney, liver and cardiac disease models [70-73]. There is an equilibrium between BMP 7 and TGF-β in control of EMT process [42]. Both molecules bind to threonine kinase serine type I receptors (ALK receptors) that triggers intracellular signals mediated by different Smad proteins. In peritoneal MCs it has been shown that BMP 7 reverses EMT [73].

**Mammalian target of rapamycin (mTOR) inhibitors [74]:** mTOR signal results in hypoxia-inducible factor 1 (HIF-1) and RORγt (transcription factor retinoic acid-related orphan receptor γt) activation, this event causes IL17 and 23.

**Peroxisome proliferator-activated receptor γ (PPAR):** it inhibits THC17 differentiation by blocking Stat 3 cascade, and provokes a RORγt down regulation and a decrease in IL 17 production [76]. COX-2 inhibitors (Celecoxib) [77]: it is a RORγt inhibitor (Celecoxib) [77]: it is considered an inflammatory inhibitor in animal models (mice).

**Other treatments:** Inhibition of the renin angiotensin aldosterone system, NF-κB, blocking TGF-β(SnoN and Ski block Smad signal), SOCS (inhibitor of JAK / STAT signal), pentoxifylline.

**Conflict of Interest**

The authors declare no conflict of interest. None

**References**

20. Su Mi, Zhe Li, Hong-Zhen Yang, Hong Liu, Jia-Ping Wang, et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGFβ1-dependent and -independent mechanisms. Journal of Immunology 2011;187(6):3030-3034.
Fibrosis in Chronic Kidney Disease. Protagonista and Therapy


